Pacira Pharmaceuticals (NASDAQ:PCRX)

CAPS Rating: 2 out of 5


Player Avatar zzlangerhans (99.85) Submitted: 8/8/2011 5:18:34 PM : Outperform Start Price: $9.01 PCRX Score: +7.66

One of my strategies to come out ahead in the current decline is to find stocks that have been beaten down severely but have potential strong catalysts before the end of the year. Pacira's catalyst is the October 28 PDUFA for Exparel long-acting bupivacaine for post-operative pain management. The NDA is supported by strong phase III data in bunionectomy and hemorrhoidectomy. Pacira's fall from highs of 15 was prompted by a three month delay in the PDUFA, and the drop has accelerated dramatically this week. However, I feel that the likelihood of approval is about 70%, and with a market cap of 150M and cash of 50M Pacira is unlikely to see a sell-off after a positive FDA decision. Unlike other newly approved pain medications which have to compete in a crowded niche, Exparel seems to be a fairly straightforward upgrade in immediate post-operative pain management.

Member Avatar PatientTrader (< 20) Submitted: 2/28/2012 9:44:27 AM
Recs: 0

People have missed the mark on this stock, I show with in 3 years revenue will be at least $300 million and growing world wide sales will be potential $700 million and I believe could hit $1 billion.

Featured Broker Partners